← All trials
NCT04685616
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Apr 30, 2030
- Completion date
- Apr 30, 2032
- First posted
- Dec 28, 2020
- Last posted
- Oct 4, 2021
- Enrollment
- 1042
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Canadian Cancer Trials GroupCollaborator
- TakedaCollaborator
- University of ManchesterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.